Syringe Service Program Plus a Harm Reduction Kiosk Intervention for Sexually Transmitted Infections
This trial tests a community-tailored kiosk to reduce HIV, hepatitis C, and overdose risk in Appalachian Kentucky, an area at the center of the injection drug use, overdoses, and hepatitis C crises.
- Sexually Transmitted Infections (STIs)
- Drug Overdose
- Opioid Use Disorder
- Hepatitis C
- Substance Abuse
- Intravenous Drug Use
- Opiate Substitution Therapy
3 Primary · 15 Secondary · Reporting Duration: Measured at baseline and then every 6 months up to 5 years
2 Treatment Groups
Syringe Service Program
1 of 2
Syringe Service Program Plus a Harm Reduction Kiosk Intervention
1 of 2
700 Total Participants · 2 Treatment Groups
Primary Treatment: Syringe Service Program Plus a Harm Reduction Kiosk Intervention · No Placebo Group · N/A
Who is running the clinical trial?
Age 18+ · All Participants · 1 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What is the current number of individuals being trialed with this intervention?
"Affirmative, the trial is still in progress according to clinicaltrials.gov. It was first posted on March 6th 2023 and revised most recently on March 7th of the same year. A total of 700 participants are required from one primary site for this research project." - Anonymous Online Contributor
Are any additional participants being accepted for this trial?
"By referencing clinicaltrials.gov, it is evident that this trial has initiated its recruitment phase; the listing was created on March 6th 2023 and most recently updated one day later." - Anonymous Online Contributor
To what purpose is this clinical trial geared?
"This clinical trial, whose results will be evaluated over a five-year span from baseline, aims to assess the alteration in syringe coverage for injectable drugs. Secondary objectives include examination of changes in overdose frequency (measured as self-reported incidents within six months), modification in MOUD usage (defined by self-reported days taking medications for opioid use disorder), and alterations with regards to linkage to treatment among those who test HCV positive that have never received therapy before (binary)." - Anonymous Online Contributor